EECP对冠心病患者血浆Lp-PLA2和hsCRP水平的影响

Influence of EECP on plasma levels of Lp-PLA2 and hsCRP in patients with coronary heart disease

目的:观察增强型体外反搏(EECP)对冠心病(CHD)患者血浆脂蛋白相关磷脂酶A2(Lp-PLA2)及超敏C反应蛋白(hsCRP)水平的影响,初步探讨EECP防治CHD的抗炎作用机制。方法:选择我院的CHD患者85例,随机分为常规治疗组(42例)和EECP组[43例,常规治疗基础上加用EECP治疗,每天1次,每次反搏治疗60min,连续5周1个疗程(35次)]。所有研究对象在入选当天及治疗5周结束后测定血浆Lp-PLA2和hsCRP浓度。结果:与治疗前比较,治疗5周后EECP组血浆Lp-PLA2[(58.46±40.04)μg/L比(33.94±23.22)μg/L]和hsCRP[(3.54±2.22)μg/ml比(2.19±1.16)μg/ml]水平明显降低(P均<0.01),常规治疗组治疗前后无明显变化。治疗5周后与常规治疗组比较,EECP组血浆Lp-PLA2[(56.87±33.69)μg/L比(33.94±23.22)μg/L]和hsCRP[(3.63±1.60)μg/ml比(2.19±1.16)μg/ml]水平降低更显著,P均<0.01。结论:增强型体外反搏治疗一疗程可明显降低冠心病患者血浆脂蛋白相关磷脂酶和超敏C反应蛋白浓度,提示抗炎可能是其防治冠心病的机制之一。

Objective： To observe influence of enhanced external counterpulsation （EECP） on plasma levels of lipo- protein- associated phospholipase A2 （Lp-PLA2） and hsCRP in patients with coronary heart disease （CHD）, and preliminarily explore anti- inflammatory mechanism of EECP in prevention and treatment of CHD. Methods： A to- tal of 85 CHD patients were selected from our hospital, randomly divided into routine treatment group （n = 42） and EECP group [n = 43, received EECP based on routine treatment, once/d, 60min each time, continuous five weeks were regarded as one course （35 times）]. Plasma concentrations of Lp-PLA2 and hsCRP were measured in all sub- jects at the enrollment day and after five- week treatment. Results： Compared with before treatment, after five- week treatment, there were significant reductions in plasma levels of Lp-PLA2 [ （58.46 ± 40.04） μg/L vs. （33.94 ± 23.22） μg/L] and hsCRP [ （3.54 ±2.22） μg/ml vs. （2.19 ±1.16） μg/ml] in EECP group （P〈0.01 both）, and there were no significant difference in routine treatment group between before and after treatment. Compared with routine treatment group, after five- week treatment, there were significant reductions in plasma levels of Lp-PLA2 [ （56.87 ± 33.69） μg/L vs. （33.94 ± 23.22） μg/L] and hsCRP [ （3.63 ± 1.60） μg/ml vs. （2.19 ± 1.16） μg/ml] in EECP group, P（0.01 both. Conclusion： 1. EECP of one course can significantly reduce plasma concentrations of Lp-PLA2 and hsCRP in CHD patients, indicating that anti- inflammatory may be one of its mechanism in preven- tion and treatment of CHD.